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Introduction: The detection of mutations in the epidermal growth
factor receptor (EGFR) gene, which predict sensitivity to treatment
with EGFR tyrosine kinase inhibitors, represents a major advance in
the treatment of lung adenocarcinoma. KRAS mutations confer
resistance to EGFR-tyrosine kinase inhibitors. The prevalence of
these mutations in African American patients has not been thor-
oughly investigated.
Methods: We collected formalin-fixed, paraffin-embedded material
from resected lung adenocarcinomas from African American pa-
tients at three institutions for DNA extraction. The frequencies of
EGFR exon 19 deletions, exon 21 L858R substitutions, and KRAS
mutations in tumor specimens from African American patients were
compared with data in white patients (n  476).
Results: EGFR mutations were detected in 23 of the 121 specimens
from African American patients (19%, 95% confidence interval
[CI]: 13–27%), whereas KRAS mutations were found in 21 (17%,
95% CI: 12–25%). There was no significant difference between
frequencies of EGFR mutations comparing African American and
white patients, 19% versus 13% (61/476, 95% CI: 10–16%; p 
0.11). KRAS mutations were more likely among whites, 26% (125/
476, 95% CI: 23–30%; p  0.04).
Conclusions: This is the largest study to date examining the fre-
quency of mutations in lung adenocarcinomas in African Americans.
Although KRAS mutations were somewhat less likely, there was no
difference between the frequencies of EGFR mutations in African
American patients, when compared with whites. These results sug-
gest that all patients with advanced lung adenocarcinomas should
undergo mutational analysis before initiation of therapy.
Key Words: EGFR mutation, KRAS, African Americans, Racial
differences.
(J Thorac Oncol. 2011;6: 28–31)
The discovery of activating mutations in the epidermalgrowth factor receptor (EGFR) gene has revolutionized
our understanding and treatment of lung adenocarcinoma, a
disease diagnosed in 120,000 Americans each year.1 Somatic
mutations in the tyrosine kinase domain of the EGFR gene
drive the development of a substantial subset of lung adeno-
carcinomas and sensitize these tumors to treatment with the
small molecule tyrosine kinase inhibitors (TKIs) erlotinib and
gefitinib.2–4 When patients with EGFR mutations are treated
with EGFR-TKIs, nearly all respond, with improvement in
progression-free survival compared with patients without
EGFR mutations.5 As a result, there has been significant
interest in molecular characterization of EGFR and in iden-
tification of patients with EGFR mutations.
Approximately one third of lung adenocarcinomas
worldwide and an estimated 50% of tumors from East Asian
patients have EGFR mutations. Nevertheless, only 15% of
patients from an unselected North American population will
harbor these mutations.6 The prevalence of EGFR mutations
among patients of other races, such as African Americans, is
unknown, in part due to small numbers of patients included
and/or reported in prior studies.
KRAS mutations are also of interest in patients with
lung adenocarcinomas. Transversion mutations (substitution
of a pyrimidine for a purine or purine for a pyrimidine) are
more common than transition mutations (substitutions of a
purine for a purine or pyrimidine for a pyrimidine). KRAS
mutations and EGFR mutations are mutually exclusive, and
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the presence of a KRASmutation identifies a group of patients
who are unlikely to respond to an EGFR-TKI.7–9Although
EGFR mutations are found more typically in never smokers,
KRAS mutations were first identified among patients who
reported heavy tobacco use. More recently, however, KRAS
mutations have also been identified in 15% of never smokers,
when compared with 22% of former smokers in one study
from our institution.10 KRAS mutations are found in 20 to
30% of patients with lung cancer in North American popu-
lations, and in Asian populations, they are less frequently
reported. The true prevalence of KRAS mutations among
African Americans is unknown.
In a prior study of 291 tumors obtained from patients
from Memorial Sloan-Kettering Cancer Center (MSKCC), 6
of 14 African Americans (43%) harbored EGFR mutations in
their tumors.11 On the basis of this higher than expected
frequency, we aimed to study the rate of both EGFR and
KRAS mutations in the largest cohort of African American
patients with lung adenocarcinoma to date.
METHODS
Tumor specimens were obtained from all available
tissue from African American patients from two institutions
MSKCC (New York, NY) and SUNY Downstate Medical
Center (Brooklyn, NY) and population-based cases from
studies conducted at Wayne State University (Detroit, MI).
African American patients were selected based on self-report
of race, as determined at the time of registration. The histo-
logic diagnosis of adenocarcinoma was verified using the
pathology report provided by participating institutions.
Approval from the MSKCC Institutional Review
Board/Privacy Board was obtained for the acquisition and
analysis of all tumor specimens. All mutational analysis was
performed in the Department of Pathology at MSKCC from
formalin-fixed, paraffin-embedded material. Tumor specimen
only underwent microdissection before mutational analysis
when necessary. EGFR exon 19 deletions and exon 21 L858R
mutations were identified using previously reported mutation-
specific polymerase chain reaction-based methods.12,13 KRAS
codon 12 and codon 13 mutation identification was per-
formed by both mass spectrometry (Sequenom)-based geno-
typing and direct sequencing. All positive cases were identi-
fied by visual review and independently confirmed by direct
sequencing.
EGFR and KRAS mutation frequencies were calculated
and compared with mutation frequencies of surgically re-
sected lung adenocarcinomas collected from white patients
evaluated at MSKCC between 2006 and 2008. Mutational
analysis of these tumors was also performed by the Depart-
ment of Pathology.
The frequency of EGFR and KRAS mutations was
summarized and compared using 2 tests and 95% confidence
intervals (CIs).
RESULTS
One hundred twenty-one lung adenocarcinomas from
African American patients were collected—approximately
equal numbers from MSKCC (n  50) and Wayne State
University (n  47), with additional samples from SUNY
Downstate Medical Center (n  24). No other clinicopatho-
logic data were collected for this analysis.
EGFR exon 19 deletions or exon 21 L858R mutations
were identified in 23 (19%) of the 121 African American
specimens (95% CI: 13–27%). Among the EGFR mutations,
18 had exon 19 deletions and five had exon 21 L858R
mutations. KRAS exon 2 codon 12 and 13 mutations were
identified in 21 (17%, 95% CI: 12–25%) of the 121 African
American tumor specimens (Table 1).
To evaluate mutation rates by race, we compared the
data collected from African American patient samples to
mutation frequencies of all lung adenocarcinomas resected
from white patients between 2006 and 2008 at MSKCC, a
total of 476 patients (Figure 1). The prevalence of KRAS
mutations in African American patients was less than that
observed in the white group (26%, 125/476, 95% CI: 23–
30%; p  0.04). Nevertheless, there was no difference in the
number of EGFR mutations between African American and
white patients (13%, 61/476, 95% CI: 10–16%; p  0.11).
Transversion mutations were demonstrated in 17 (81%,
95% CI: 59–93%) of the African American patients harbor-
ing KRAS mutant lung cancers, and only four (19%, 95% CI:
7–41%) had transition mutations. Similarly, 87 (70%, 95%
CI: 62–78%) of KRAS mutations in the white cohort were
transversions, whereas 37 (30%, 95% CI: 22–38%) were
transitions (p  0.44). The distribution of KRAS mutations
and their frequencies in both cohorts are listed in Table 2. The
most common type of KRAS mutation found in both cohorts
was the glycine to cysteine transversion (G12C). The least
common KRAS mutations were G13V, G12R, G12S, and
FIGURE 1. Frequencies of EGFR and KRAS mutations among
African American and white populations.
TABLE 1. Distribution and Frequency of Mutations Among
African Americans
Mutations Identified
African
Americans
(n  121)
95% CI
(%)
EGFR exon 19 deletion, n (%) 18 (15%) 10–22
EGFR L858R exon 21 mutation, n (%) 5 (4%) 2–10
KRAS mutations, n (%) 21 (17%) 12–25
EGFR/KRAS wild type, n (%) 66 (55%) 46–63
CI, confidence interval; EGFR, epidermal growth factor receptor.
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G13S. Of these, only G13S was not represented in the larger
white group.
DISCUSSION
This study represents the largest retrospective study to
date comparing EGFR and KRAS mutation rates between
African American and white populations. There was no
difference in the frequency of EGFR mutations between the
African American and white cohorts, whereas KRAS muta-
tions were less frequent among African American patients.
A few small studies have previously evaluated the
prevalence of mutations by race. In one study performed in
Louisiana, the frequency of KRASmutations was evaluated in
116 patients with lung cancer, 60 of them were African
Americans.14 In contrast to our findings, African American
patients in that study were significantly more likely to harbor
a KRAS mutation, when compared with white patients (37%
versus 20%, p  0.048). Nevertheless, consistent with our
data and reports by others, Hunt et al.14 also reported a
“disproportionately high number of cysteine for glycine
transversions.” Cysteine missense substitutions result from a
G3T transversion in the first base in either codon 12 or 13.
They have been attributed to the polycyclic aromatic hydro-
carbons present in tobacco smoke.15 Hunt et al.14 also found
a higher than expected number of serine mutations among the
African American cohort as the result of a G3A transition in
the first base of either codon 12 or 13. This mutation was
demonstrated in one African American patient in this study
and one patient in our white cohort (Table 2).
Racial differences in EGFR mutation rates have also
been evaluated in smaller numbers in prior studies (Table 3).
EGFR mutations were reported in 1 of 44 African American
patients (2.4%) in a study of 219 patients with tissue speci-
men from the University of Maryland, the Mayo Clinic in
Minnesota, and the University of Milan, Italy.16 In compari-
son, 25 of the 177 (14.1%) tumors from white patients
harbored EGFR mutations. Another study from the Univer-
sity of Texas M. D. Anderson Cancer Center included only
eight African American patients.17 Although 14 EGFR mu-
tations were confirmed among the 159 patients included,
none were reported in this small subset of African American
patients. Although KRAS mutations were also reported in 18
patients overall, their races were not specified.
Most recently, Leidner et al.18 published an analysis of
53 tumors from African American patients obtained from the
University Hospitals Case Medical Center in Cleveland, OH.
Patients were selected based on the availability of a tissue
block and uninvolved paired tissue (i.e., from a lymph node).
Results were compared with a white cohort of 121 patients
from three separate Italian centers (Bologna, Milan, and
Perugia) previously enrolled in an unrelated clinical trial to
receive gefitinib, who had mutational analysis performed
previously. In this study, African Americans were again less
likely to have EGFR mutations in their tumors, when com-
pared with white patients (2% versus 17%, p  0.022).
Nevertheless, the only EGFR mutation found among the
African American patients was neither of the common acti-
vating EGFR mutations (exon 19 deletion or exon 21 L858R
substitution) but a missense mutation in exon 20 L768N, a
mutation in EGFR not previously reported. Leidner et al. also
reported no difference in KRASmutation frequencies between
the two cohorts of patients.
Twice the number of African American patients (n 
121) were included in our analysis compared with 53 tumors
from African American patients tested in the article of
Leidner et al. Although not as robust a sample as our white
cohort, a retrospective power calculation indicates that we
have adequate power to detect a difference of 9.6% or
more in either direction, assuming the frequency of EGFR
mutations in the white population is 13%. Therefore, if it
were true that EGFR mutations exist among African Amer-
ican patients at a much lower frequency, as reported in
TABLE 2. Distribution of KRAS Mutations Among Whites
and African American Patients
KRAS
Mutation
KRAS
Nucleotide
African American
Patients
(n  21)
White
Patients
(n  125) p
G12C GGT3TGT 8 (38%) 48 (38%) 1
G12V GGT3GGT 7 (33%) 18 (14%) 0.0547
G12A GGT3GCT 1 (5%) 13 (10%) a
G13C GGC3TGC 1 (5%) 7 (6%) a
G13V GGC3GTC 0 (0%) 1 (1%) a
G12R GGT3CGT 0 (0%) 1 (1%) a
G12D GGT3GAT 3 (14%) 32 (26%) a
G13D GGC3GAC 0 (0%) 4 (3%) a
G12S GGT3AGT 0 (0%) 1 (1%) a
G13S GGC3AGC 1 (5%) 0 (0%) a
a Numbers are too small for meaningful comparison.
AA, African American.
TABLE 3. Prior Studies Comparing the Frequencies of EGFR Mutations in African American and White Patients
Study
African American
Patients White Patients
Frequency EGFR Mutations,
African American Patients, n (%)
Frequency EGFR Mutation,
White Patients, n (%)
Yang et al.16 41 177 1 (2.4), 95% CI: 0–12.9% 25 (14%), 95% CI: 9.4–20.1%
Tsao et al.17 8 139 0 (0), 95% CI: 0–40% 10 (7%), 95% CI: 4–13%
Leidner et al.18 53 102 1 (2), 95% CI: 0–11% 15 (17%a), 95% CI: 11–26%
Reinersman et al. (this study) 121 476 23 (19), 95% CI: 13–27% 61 (13%), 95% CI: 10–16%
a Eighty-nine of 102 whites analyzable for EGFR mutations.
CI, confidence interval; EGFR, epidermal growth factor receptor.
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previous studies (Table 3), we would have detected that
difference in our analysis.
One potential source of bias in our study is the fact
that African American specimens were collected from
three different centers, whereas white patients were col-
lected only from MSKCC. Similar to the study by Leidner
et al. described earlier, patients were included based solely
on tissue availability, a common criterion for translational
tissue studies. No other sample selection was used, and
because all African American patients who had available
tissue were included, we expect the study population to be
representative of the African American population of each
participating institution. An analysis restricted to MSKCC
patients found 16% of African Americans had EGFR
mutations, and 25% had KRAS mutations, both safely
within the 95% CIs for the total number of African
American patients included in the results.
We did not report clinical characteristics traditionally
associated with response to EGFR-TKIs in our patients.
Before the IRESSA Pan-Asian Study, we relied on histology,
ethnicity, and smoking status to predict the likelihood of
response to EGFR-TKI treatment. Nevertheless, we now
know that it is the presence of the EGFR mutation that truly
underlies sensitivity. The most meaningful demonstration of this
principle from IPASS was the paltry response (1%) of Asian
women never smokers or former light smokers randomized to
receive gefitinib who were found to be without EGFR mutations
in their tumors.5 Testing tumors for the presence of EGFR and
KRASmutations before treatment with the EGFR-TKI gefitinib
is now a standard of care in Europe. This standard will
increasingly be adopted on all continents, and therefore,
attention to clinical characteristics for the purposes of
predicting response to EGFR-TKIs will continue to lessen
in importance.
Our data indicate that lung cancers arise from EGFR
mutations in African Americans just as commonly as in white
patients. Therefore, African American patients stand to derive
similar benefit from treatment with EGFR-TKIs as other
western populations. We believe that these results have im-
portant diagnostic and treatment implications for African
American patients and any non-Asian, non-white patients
with lung cancer. Irrespective of race, tumors tissue obtained
from all patients with advanced lung adenocarcinoma should
be screened for the presence of EGFR and KRAS mutations.
Future research efforts examining other molecular mecha-
nisms, such as MET germline polymorphisms,19 BRAF mu-
tations, HER2 mutations, and ALK translocations, may fur-
ther elucidate the racial variations in lung cancer
development.
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